Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials.

39 Additionally, the trial did not meet its prespecified endpoint of improved median PFS, though there was a clear trend in the direction of longer PFS with pembrolizumab (the median PFS with pembrolizumab was 16.0 months compared with 10.3 months with placebo). 39 It is notable that more patients receiving pembrolizumab had responses lasting longer than 18 months than those receiving placebo (60% versus 28%). 39 Gr

also in 19,460 other papers